Industry: Pharma & Healthcare
Published Date: 2024-01-17
Pages: 89 Pages
Report ld: 2271400
Request Sample
Customized Report
Transthyretin Stabilizer Market Size(US$)

CAGR 2024-2030
6.9%
Market Size,2030
USD 2,372.8
Million
Market Snapshot
Source: Secondary research, interviews with experts, and QYResearch analysis
Transthyretin found in serum and cerebrospinal fluid of body is one of the transport protein carrying thyroxine and retinol-binding proteins. Transthyretin destabilization can take place due to inherited mutations or ageing.Transthyretin stabilizers prevent destabilization of protein and amyloidosis progression.A transthyretin (TTR) stabilizer is a type of medication or compound that is used in the treatment of transthyretin amyloidosis (ATTR), a rare genetic disorder characterized by the deposition of abnormal TTR protein in various organs and tissues.
TTR stabilizers work by binding to and stabilizing the TTR protein, preventing it from misfolding and forming amyloid fibrils. By stabilizing the TTR protein, these medications aim to slow down or halt the progression of the disease and potentially alleviate symptoms.
The global Transthyretin Stabilizer market was valued at US$ 1480 million in 2023 and is anticipated to reach US$ 2372.8 million by 2030, witnessing a CAGR of 6.9% during the forecast period 2024-2030.
The global transthyretin stabilizer market refers to the market for medications and compounds used in the treatment of transthyretin amyloidosis (ATTR) by stabilizing the transthyretin (TTR) protein. This market encompasses various drugs that have been developed or under development as TTR stabilizers.
Currently, there are several TTR stabilizers that have gained regulatory approval or are in advanced stages of clinical development. The market is primarily driven by the rising prevalence of ATTR, increasing awareness of the disease, and the need for effective treatment options.
One of the key drugs in the market is tafamidis, which is approved in several countries for the treatment of ATTR polyneuropathy. Tafamidis has shown to stabilize TTR and slow disease progression in clinical trials. Other drugs such as diflunisal, AG10, inotersen, and patisiran are also being investigated and have shown promising results in clinical studies.
The market is expected to witness significant growth as more research is conducted on the development of TTR stabilizers and as regulatory approvals are obtained for these drugs in different regions. Additionally, the ongoing efforts to increase disease awareness among healthcare professionals and patients are likely to contribute to the market growth.
Key players in the global transthyretin stabilizer market include pharmaceutical companies such as Pfizer Inc., Alnylam Pharmaceuticals, Inc., Eidos Therapeutics, and Ionis Pharmaceuticals Inc., among others. These companies invest in research and development activities to develop new TTR stabilizers and expand their product portfolios.
Geographically, North America and Europe are leading regions in the market, primarily due to the higher prevalence of ATTR and the presence of established healthcare infrastructure. However, as awareness and diagnosis of ATTR improve in other regions such as Asia Pacific and Latin America, these regions are likely to exhibit significant growth opportunities.
In conclusion, the global transthyretin stabilizer market is expected to grow as more effective treatments are developed and approved for ATTR. The market is driven by the increasing prevalence of the disease and the need for therapies that can stabilize the TTR protein and slow disease progression.
This report aims to provide a comprehensive presentation of the global market for Transthyretin Stabilizer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Transthyretin Stabilizer.
MARKET SEGMENTATION
REPORT SCOPE
The Transthyretin Stabilizer market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Transthyretin Stabilizer market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Transthyretin Stabilizer manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
CHAPTER OUTLINE
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Transthyretin Stabilizer manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Transthyretin Stabilizer in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
QYRESEARCH'S STRENGTHS
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
We identify regional market threats and growth prospects to guide your overseas layout.
We adjust product portfolios in line with local consumption habits.
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
TABLE OF CONTENTS
1 Transthyretin Stabilizer Market Overview
1.1 Product Overview and Scope of Transthyretin Stabilizer
1.2 Transthyretin Stabilizer Segment by Type
1.2.1 Global Transthyretin Stabilizer Market Value Comparison by Type (2024-2030)
1.2.2 Diflunisal
1.2.3 Tafamidis
1.2.4 Others
1.3 Transthyretin Stabilizer Segment by Application
1.3.1 Global Transthyretin Stabilizer Market Value by Application: (2024-2030)
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Drug Stores
1.3.5 Online Pharmacies
1.3.6 Others
1.4 Global Transthyretin Stabilizer Market Size Estimates and Forecasts
1.4.1 Global Transthyretin Stabilizer Revenue 2019-2030
1.4.2 Global Transthyretin Stabilizer Sales 2019-2030
1.4.3 Global Transthyretin Stabilizer Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Transthyretin Stabilizer Market Competition by Manufacturers
2.1 Global Transthyretin Stabilizer Sales Market Share by Manufacturers (2019-2024)
2.2 Global Transthyretin Stabilizer Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Transthyretin Stabilizer Average Price by Manufacturers (2019-2024)
2.4 Global Transthyretin Stabilizer Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Transthyretin Stabilizer, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Transthyretin Stabilizer, Product Type & Application
2.7 Transthyretin Stabilizer Market Competitive Situation and Trends
2.7.1 Transthyretin Stabilizer Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Transthyretin Stabilizer Players Market Share by Revenue
2.7.3 Global Transthyretin Stabilizer Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Transthyretin Stabilizer Retrospective Market Scenario by Region
3.1 Global Transthyretin Stabilizer Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Transthyretin Stabilizer Global Transthyretin Stabilizer Sales by Region: 2019-2030
3.2.1 Global Transthyretin Stabilizer Sales by Region: 2019-2024
3.2.2 Global Transthyretin Stabilizer Sales by Region: 2025-2030
3.3 Global Transthyretin Stabilizer Global Transthyretin Stabilizer Revenue by Region: 2019-2030
3.3.1 Global Transthyretin Stabilizer Revenue by Region: 2019-2024
3.3.2 Global Transthyretin Stabilizer Revenue by Region: 2025-2030
3.4 North America Transthyretin Stabilizer Market Facts & Figures by Country
3.4.1 North America Transthyretin Stabilizer Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Transthyretin Stabilizer Sales by Country (2019-2030)
3.4.3 North America Transthyretin Stabilizer Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Transthyretin Stabilizer Market Facts & Figures by Country
3.5.1 Europe Transthyretin Stabilizer Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Transthyretin Stabilizer Sales by Country (2019-2030)
3.5.3 Europe Transthyretin Stabilizer Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Transthyretin Stabilizer Market Facts & Figures by Country
3.6.1 Asia Pacific Transthyretin Stabilizer Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Transthyretin Stabilizer Sales by Country (2019-2030)
3.6.3 Asia Pacific Transthyretin Stabilizer Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Transthyretin Stabilizer Market Facts & Figures by Country
3.7.1 Latin America Transthyretin Stabilizer Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Transthyretin Stabilizer Sales by Country (2019-2030)
3.7.3 Latin America Transthyretin Stabilizer Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Transthyretin Stabilizer Market Facts & Figures by Country
3.8.1 Middle East and Africa Transthyretin Stabilizer Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Transthyretin Stabilizer Sales by Country (2019-2030)
3.8.3 Middle East and Africa Transthyretin Stabilizer Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Transthyretin Stabilizer Sales by Type (2019-2030)
4.1.1 Global Transthyretin Stabilizer Sales by Type (2019-2024)
4.1.2 Global Transthyretin Stabilizer Sales by Type (2025-2030)
4.1.3 Global Transthyretin Stabilizer Sales Market Share by Type (2019-2030)
4.2 Global Transthyretin Stabilizer Revenue by Type (2019-2030)
4.2.1 Global Transthyretin Stabilizer Revenue by Type (2019-2024)
4.2.2 Global Transthyretin Stabilizer Revenue by Type (2025-2030)
4.2.3 Global Transthyretin Stabilizer Revenue Market Share by Type (2019-2030)
4.3 Global Transthyretin Stabilizer Price by Type (2019-2030)
5 Segment by Application
5.1 Global Transthyretin Stabilizer Sales by Application (2019-2030)
5.1.1 Global Transthyretin Stabilizer Sales by Application (2019-2024)
5.1.2 Global Transthyretin Stabilizer Sales by Application (2025-2030)
5.1.3 Global Transthyretin Stabilizer Sales Market Share by Application (2019-2030)
5.2 Global Transthyretin Stabilizer Revenue by Application (2019-2030)
5.2.1 Global Transthyretin Stabilizer Revenue by Application (2019-2024)
5.2.2 Global Transthyretin Stabilizer Revenue by Application (2025-2030)
5.2.3 Global Transthyretin Stabilizer Revenue Market Share by Application (2019-2030)
5.3 Global Transthyretin Stabilizer Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Pfizer Inc.
6.1.1 Pfizer Inc. Corporation Information
6.1.2 Pfizer Inc. Description and Business Overview
6.1.3 Pfizer Inc. Transthyretin Stabilizer Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Pfizer Inc. Transthyretin Stabilizer Product Portfolio
6.1.5 Pfizer Inc. Recent Developments/Updates
6.2 Merck & Co.
6.2.1 Merck & Co. Corporation Information
6.2.2 Merck & Co. Description and Business Overview
6.2.3 Merck & Co. Transthyretin Stabilizer Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Merck & Co. Transthyretin Stabilizer Product Portfolio
6.2.5 Merck & Co. Recent Developments/Updates
6.3 AstraZeneca Plc.
6.3.1 AstraZeneca Plc. Corporation Information
6.3.2 AstraZeneca Plc. Description and Business Overview
6.3.3 AstraZeneca Plc. Transthyretin Stabilizer Sales, Revenue and Gross Margin (2019-2024)
6.3.4 AstraZeneca Plc. Transthyretin Stabilizer Product Portfolio
6.3.5 AstraZeneca Plc. Recent Developments/Updates
6.4 GlaxoSmithKline Plc.
6.4.1 GlaxoSmithKline Plc. Corporation Information
6.4.2 GlaxoSmithKline Plc. Description and Business Overview
6.4.3 GlaxoSmithKline Plc. Transthyretin Stabilizer Sales, Revenue and Gross Margin (2019-2024)
6.4.4 GlaxoSmithKline Plc. Transthyretin Stabilizer Product Portfolio
6.4.5 GlaxoSmithKline Plc. Recent Developments/Updates
6.5 Corino Therapeutics Inc.
6.5.1 Corino Therapeutics Inc. Corporation Information
6.5.2 Corino Therapeutics Inc. Description and Business Overview
6.5.3 Corino Therapeutics Inc. Transthyretin Stabilizer Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Corino Therapeutics Inc. Transthyretin Stabilizer Product Portfolio
6.5.5 Corino Therapeutics Inc. Recent Developments/Updates
6.6 Alnylam Pharmaceuticals
6.6.1 Alnylam Pharmaceuticals Corporation Information
6.6.2 Alnylam Pharmaceuticals Description and Business Overview
6.6.3 Alnylam Pharmaceuticals Transthyretin Stabilizer Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Alnylam Pharmaceuticals Transthyretin Stabilizer Product Portfolio
6.6.5 Alnylam Pharmaceuticals Recent Developments/Updates
6.7 Bellus Health Inc.
6.6.1 Bellus Health Inc. Corporation Information
6.6.2 Bellus Health Inc. Description and Business Overview
6.6.3 Bellus Health Inc. Transthyretin Stabilizer Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Bellus Health Inc. Transthyretin Stabilizer Product Portfolio
6.7.5 Bellus Health Inc. Recent Developments/Updates
6.8 Ionis Pharmaceuticals, Inc.
6.8.1 Ionis Pharmaceuticals, Inc. Corporation Information
6.8.2 Ionis Pharmaceuticals, Inc. Description and Business Overview
6.8.3 Ionis Pharmaceuticals, Inc. Transthyretin Stabilizer Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Ionis Pharmaceuticals, Inc. Transthyretin Stabilizer Product Portfolio
6.8.5 Ionis Pharmaceuticals, Inc. Recent Developments/Updates
6.9 Proclara Bioscience
6.9.1 Proclara Bioscience Corporation Information
6.9.2 Proclara Bioscience Description and Business Overview
6.9.3 Proclara Bioscience Transthyretin Stabilizer Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Proclara Bioscience Transthyretin Stabilizer Product Portfolio
6.9.5 Proclara Bioscience Recent Developments/Updates
6.10 Arturus Therapeutics
6.10.1 Arturus Therapeutics Corporation Information
6.10.2 Arturus Therapeutics Description and Business Overview
6.10.3 Arturus Therapeutics Transthyretin Stabilizer Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Arturus Therapeutics Transthyretin Stabilizer Product Portfolio
6.10.5 Arturus Therapeutics Recent Developments/Updates
6.11 Prothena Corporation Plc.
6.11.1 Prothena Corporation Plc. Corporation Information
6.11.2 Prothena Corporation Plc. Transthyretin Stabilizer Description and Business Overview
6.11.3 Prothena Corporation Plc. Transthyretin Stabilizer Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Prothena Corporation Plc. Transthyretin Stabilizer Product Portfolio
6.11.5 Prothena Corporation Plc. Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Transthyretin Stabilizer Industry Chain Analysis
7.2 Transthyretin Stabilizer Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Transthyretin Stabilizer Production Mode & Process
7.4 Transthyretin Stabilizer Sales and Marketing
7.4.1 Transthyretin Stabilizer Sales Channels
7.4.2 Transthyretin Stabilizer Distributors
7.5 Transthyretin Stabilizer Customers
8 Transthyretin Stabilizer Market Dynamics
8.1 Transthyretin Stabilizer Industry Trends
8.2 Transthyretin Stabilizer Market Drivers
8.3 Transthyretin Stabilizer Market Challenges
8.4 Transthyretin Stabilizer Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
TABLE OF FIGURES
List of Tables
List of Figures
KEY QUESTIONS ADDRESSED BY THE REPORT
Related Reports
The global market for Transthyretin Stabilizer was valued at US$ 1590 million in the year 2024 and is projected to reach a revised size of US$ 2520 million by 2031, growing at a CAGR of 6.9% during the forecast period.
Published Date: 2025-01-01
Pages: 92
USD 2900.00
(Single User License)
Transthyretin found in serum and cerebrospinal fluid of body is one of the transport protein carrying thyroxine and retinol-binding proteins. Transthyretin destabilization can take place due to inherited mutations or ageing.Transthyretin stabilizers prevent destabilization of protein and amyloidosis progression.A transthyretin (TTR) stabilizer is a type of medication or compound that is used in the treatment of transthyretin amyloidosis (ATTR), a rare genetic disorder characterized by the deposition of abnormal TTR protein in various organs and tissues.
Published Date: 2024-04-12
Pages: 112
USD 4900.00
(Single User License)
Transthyretin found in serum and cerebrospinal fluid of body is one of the transport protein carrying thyroxine and retinol-binding proteins. Transthyretin destabilization can take place due to inherited mutations or ageing.Transthyretin stabilizers prevent destabilization of protein and amyloidosis progression.A transthyretin (TTR) stabilizer is a type of medication or compound that is used in the treatment of transthyretin amyloidosis (ATTR), a rare genetic disorder characterized by the deposition of abnormal TTR protein in various organs and tissues.
Published Date: 2024-01-10
Pages: 117
USD 3950.00
(Single User License)
The global market for Transthyretin Stabilizer was valued at US$ 1590 million in the year 2024 and is projected to reach a revised size of US$ 2520 million by 2031, growing at a CAGR of 6.9% during the forecast period.
Published: 2025-01-01
Pages: 92
Transthyretin found in serum and cerebrospinal fluid of body is one of the transport protein carrying thyroxine and retinol-binding proteins. Transthyretin destabilization can take place due to inherited mutations or ageing.Transthyretin stabilizers prevent destabilization of protein and amyloidosis progression.A transthyretin (TTR) stabilizer is a type of medication or compound that is used in the treatment of transthyretin amyloidosis (ATTR), a rare genetic disorder characterized by the deposition of abnormal TTR protein in various organs and tissues.
Published: 2024-04-12
Pages: 112
Transthyretin found in serum and cerebrospinal fluid of body is one of the transport protein carrying thyroxine and retinol-binding proteins. Transthyretin destabilization can take place due to inherited mutations or ageing.Transthyretin stabilizers prevent destabilization of protein and amyloidosis progression.A transthyretin (TTR) stabilizer is a type of medication or compound that is used in the treatment of transthyretin amyloidosis (ATTR), a rare genetic disorder characterized by the deposition of abnormal TTR protein in various organs and tissues.
Published: 2024-01-10
Pages: 117
REPORT COVERAGE
DESCRIPTION
OVERVIEW
MARKET SEGMENTATION
REPORT SCOPE
CHAPTER OUTLINE
QYRESEARCH'S STRENGTHS
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
INTEREST IN THIS REPORT?
Get A Free Sample
Request For Quotation
OR
NEED A CUSTOMIZED REPORT?
Customized Report
Request Sample
Pre-Order Enquiry
Add to Cart
Buy Now